Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Single Organ-on-a-Chip Models - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Single Organ-on-a-Chip Models market, including market size, share, demand, industry development status, and forecasts for the next few years. The global market for Single Organ-on-a-Chip Models was estimated to be worth US185millionin2025andisprojectedtoreachUS 520 million, growing at a CAGR of 15.9% from 2026 to 2032. Single organ-on-a-chip models are microfluidic devices containing human cell cultures that recapitulate the structure, function, and physiological responses of specific organs (liver, kidney, brain, heart, lung, gut). These platforms incorporate controlled fluid flow, mechanical stimulation (shear stress, stretch), and tissue-specific architecture (tubules, alveoli, blood-brain barrier), enabling more predictive drug efficacy and safety testing than traditional 2D cultures or animal models. For pharmaceutical toxicologists and drug discovery scientists, core pain points include poor prediction of human-specific toxicities (drug-induced liver injury, nephrotoxicity, cardiotoxicity), species differences in drug metabolism, and high preclinical-to-clinical attrition (90% failure rate). Single organ-on-a-chip models address these through human-derived cells (primary, iPSC), physiologically relevant microenvironments, and functional readouts (biomarkers, electrophysiology, barrier integrity). 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5984241/single-organ-on-a-chip-models Market Segmentation: Organ Type and Application The Single Organ-on-a-Chip Models market is segmented as below: By Type: Kidney-on-a-chip | Liver-on-a-chip | Brain-on-a-chip | Heart-on-a-chip | Others (Lung, Gut, Skin) By Application: Pharmaceutical | Research Institute | Others By Key Players: Emulate, Mimetas, CN Bio Innovations, Hesperos, AxoSim, Elvesys, InSphero, Beijing Abace Biotechnology Market Size and Share Dynamics In 2025, liver-on-a-chip models dominated the Single Organ-on-a-Chip Models market, accounting for approximately 38% of global revenue. Drug-induced liver injury (DILI) is the leading cause of drug attrition and post-market withdrawal (e.g., troglitazone, felbamate). Liver chips incorporate primary human hepatocytes or iPSC-hepatocytes with sinusoidal endothelium and Kupffer cells, enabling detection of hepatotoxicity, steatosis, cholestasis, and fibrosis. Kidney-on-a-chip represented 22% of the market, addressing nephrotoxicity (e.g., cisplatin, tenofovir, calcineurin inhibitors) using proximal tubule epithelial cells with flow and shear stress. Brain-on-a-chip (blood-brain barrier model) held 18% share for CNS drug development (Alzheimer's, Parkinson's, glioblastoma). Heart-on-a-chip (cardiomyocyte contractility, electrophysiology) accounted for 15% for cardiotoxicity screening. Other organs (lung, gut, skin, pancreas) comprised 7%. From an application perspective, pharmaceutical companies represented the largest segment in 2025, contributing 72% of global demand. Leading adopters include Roche, Pfizer, Merck, AstraZeneca, Novartis, Sanofi, and Bristol-Myers Squibb. Research institutes (academic labs, CROs, government agencies) accounted for 25% of the market. Other applications (regulatory submissions, personalized medicine) comprised 3%. Regional Insights and Policy Drivers North America led with 52% market share in 2025, driven by FDA's predictive toxicology initiatives, Modernization Act 2.0, and concentration of major pharma R&D. Europe held 30% share, supported by EU's €100 million "Organs-on-Chip" research program (2023-2028) and NC3Rs funding. Asia-Pacific captured 14% with fastest projected growth (CAGR 20% through 2032), fueled by China's drug discovery ecosystem and Japan's AMED organ-chip projects. Recent policy drivers include FDA's "Innovative Science and Technology Approaches for New Animal Drug Applications" (2025) accepting organ-chip data. European Medicines Agency's "Guideline on Quality, Non-clinical and Clinical Aspects of Medicinal Products" (2025 revision) acknowledges microphysiological systems. China's NMPA 2026 guidance on "Alternative Methods for Drug Safety Assessment" includes organ-chip validation. Industry Deep Dive: Liver vs. Kidney Chip Applications Divergent assay requirements exist between liver and kidney platforms. Liver chips assess CYP450 metabolism (probe substrates: midazolam, dextromethorphan), transporter activity (MRP2, BSEP), and toxicity endpoints (ALT, AST, GGT, albumin, urea, ATP). Bile acid accumulation (cholestasis) and reactive metabolite formation are unique liver endpoints. Kidney chips focus on proximal tubule reabsorption and secretion (creatinine, glucose transport), brush border enzyme release (GGT, LAP), and injury biomarkers (KIM-1, NGAL, clusterin). Flow rate 1-10 μL/min mimics tubular flow shear (0.5-5 dyne/cm²). A 2025 study (Emulate Kidney Chip) correctly identified nephrotoxicity of 8/10 drugs (cisplatin, gentamicin, tenofovir) vs. 3/10 in static culture. Technical Deep Dive: Barrier Integrity and Endpoint Measurement Recent six-month data (December 2025 – May 2026) reveals that 48% of Single Organ-on-a-Chip Model performance complaints relate to barrier integrity variability (TEER, permeability) across chip batches, while 31% concern scaling for higher-throughput screening (96-well compatibility). TEER measurements (endothelial/epithelial resistance, Ω·cm²) indicate tight junction integrity. Blood-brain barrier chips target TEER >500 Ω·cm², gut chips >200 Ω·cm². Endpoint integration includes real-time sensors (pH, oxygen, glucose) and post-assay omics (transcriptomics, proteomics, metabolomics). Mimetas's OrganoPlate (40 chips/plate) achieves 1,000+ compounds/week screening. Emulate's S-1 platform (12 chips/module) incorporates automated media handling and imaging. InSphero's 3D InSight liver spheroids (96-well) are used for chronic toxicity (14-28 day dosing). User Case Study: Cardiotoxicity Screening A large pharmaceutical company evaluated 15 drug candidates (8 known cardiotoxic, 7 non-cardiotoxic) using heart-on-a-chip (iPSC-cardiomyocytes, microelectrode array). Endpoints: beating rate, field potential duration (FPD), conduction velocity, contractility, arrhythmia score. Chip sensitivity: 7/8 cardiotoxic detected (88%), specificity: 6/7 non-toxic correct (86%). hERG assay alone missed 3 compounds with off-target cardiotoxicity (non-hERG mediated). Compared to animal models (dog, guinea pig), chip predicted human arrhythmia risk with 85% accuracy vs. 70% for animals. Chip data contributed to IND safety assessment, replacing 25% of dog studies (annual cost savings $2 million). Competitive Landscape and Future Outlook Emulate (US) held approximately 22% market share in 2025, leading with S-1 platform (liver, kidney, brain, intestine chips). Mimetas (Netherlands, OrganoPlate) and CN Bio Innovations (UK, PhysioMimix) each hold 15-18% share. Hesperos (US) focuses on neuromuscular and multi-organ models. InSphero (Switzerland) and Elvesys (France) serve the academic market. Beijing Abace Biotechnology has gained share in China. Our exclusive observation indicates that by 2028, regulatory acceptance of single-organ-chip data for IND submissions will be standard for liver (DILI) and heart (QT prolongation) endpoints. Automated, high-throughput systems (384-well compatible, robotic integration) will emerge for primary screening. Combination with AI-based image analysis (beating rate, morphology) will reduce manual readout time. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp